CD34 Protein Incorporation in Viral Vector Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate in effectively inhibiting viral infectivity, particularly for enveloped RNA viruses like HIV and MLV, as they fail to provide a broad-spectrum antiviral solution that can be used in both in vitro and ex vivo settings to produce non-infectious or attenuated virus particles for therapeutic use.
Innovation Solution
The expression of CD34 protein in virus-producing cells leads to its incorporation into virus particles, thereby inhibiting viral infectivity by sterically hindering attachment to target cells, resulting in the production of non-infectious or attenuated virus particles that can be used as a recombinant vaccine or treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current antiviral methods are used, then viral infectivity can be inhibited to some extent, but they fail to provide broad-spectrum activity against enveloped RNA viruses
Solution Approach 1:
The patent utilizes the universal property of CD34 protein, which is naturally expressed on the surface of hematopoietic stem cells and progenitor cells, to provide broad-spectrum antiviral activity. By introducing CD34 expression into virus-producing cells, the system achieves universal protection against multiple enveloped RNA viruses including HIV and MLV, resolving the contradiction between adaptability and reliability.
Solution Approach 2:
CD34 protein acts as an intermediary molecule that mediates viral inactivation. The protein incorporates into virus particles during production and sterically blocks viral attachment to target cells, providing a mechanical barrier that is effective across different virus types while maintaining specific molecular interactions.
2Productivity
If viral vectors are used for gene delivery, then genetic material can be delivered to target cells, but the viral infectivity poses safety risks
Solution Approach 1:
The patent converts the harmful viral infectivity into a beneficial feature by using the same viral production machinery to incorporate CD34 protein into virus particles. The virus production process, which normally creates infectious particles, is harnessed to produce non-infectious particles that carry therapeutic genetic material, thereby converting the risk of infectivity into a safety mechanism.
Solution Approach 2:
CD34 protein is expressed in virus-producing cells before virus particle formation, allowing the protein to be incorporated into incoming virus particles during their assembly. This preliminary presence of CD34 prevents subsequent infectivity by blocking attachment, while the virus maintains its ability to deliver genetic material to target cells.
3Reliability
If CD34 expression vector is introduced into virus-producing cells, then viral infectivity is reduced, but the production process becomes more complex
Solution Approach 1:
The patent merges the CD34 expression function with the viral production system by co-transfecting virus-producing cells with both the viral vector and CD34 expression vector. This combination allows simultaneous production of viral particles and incorporation of CD34 protein, achieving infectivity reduction without requiring separate production steps or additional processing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces viral infection rates by 25% to 85% and offers a broad-spectrum antiviral activity against enveloped viruses, including HIV and MLV, by producing virus particles that are either non-infectious or attenuated, which can be used as a therapeutic intervention.
Implementation Method 1
CD34 incorporates into the virus particles; blocking a viral infection by the isolated virus particles, wherein the method is configured for inhibiting the viral infection of the virus of interest
Data Source
AI summary
An Embodiment relates to a method comprising: co-expressing a viral vector of a virus of interest and a CD34 expression vector into a human cell line to produce virus particles such that CD34 incorporates into the virus particles; isolating the virus particles from the human cell line; blocking a viral infection; and wherein the method is configured for inhibiting the viral infection of the virus of interest.